NRx Pharmaceuticals Stock Rises 33% on Psychiatry Clinic Acquisition

Dow Jones
01-03
 

By Katherine Hamilton

 

NRx Pharmaceuticals shares gained after the company said it would buy California psychiatry clinic Kadima Neuropsychiatry Institute.

The stock rose Thursday to $2.92, reaching a six-month high. Shares are down 36% over the past 12 months.

Kadima, based in La Jolla, Calif., is expected to become the flagship clinic for Hope Therapeutics, a mental-health-services subsidiary of NRx. Hope is planning to develop an international network of psychiatry clinics designed to treat depression, anxiety and post-traumatic stress disorder.

Once the acquisition is complete, David Feifel, Kadima's founder and chief executive, will serve as chief medical innovation officer of Hope.

Kadima was among the first psychiatry clinics to use ketamine therapy to treat central-nervous-system disorders. It also has a research division and contracts with the Department of Veterans Affairs.

 

Write to Katherine Hamilton at katherine.hamilton@wsj.com

 

(END) Dow Jones Newswires

January 02, 2025 12:22 ET (17:22 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10